甲状腺癌组织miR‑338‑3p、TCF4表达水平及与临床病理特征和预后的关系

李焱; 周义

doi:10.14188/j.1671-8852.2024.0081

您当前的位置：

首页 >

文章列表页 >

甲状腺癌组织miR‑338‑3p、TCF4表达水平及与临床病理特征和预后的关系

基础及临床医学研究 | 更新时间：2026-11-05

- 甲状腺癌组织miR‑338‑3p、TCF4表达水平及与临床病理特征和预后的关系
- Expression levels of miR‑338‑3p and TCF4 in thyroid cancer tissue and their relationship to the clinical pathological features and prognosis
- 武汉大学学报（医学版） 2025年46卷第2期页码：246-251
- 作者机构：
  
  河北北方学院附属第一医院核医学科河北张家口 075000
- 作者简介：
  
  李焱，男，1994—，主要从事甲状腺癌临床病理特征及核医学诊治研究，E‑mail：ly18631347961@126.com
- 基金信息：
  
  河北省2022年度医学科学研究课题计划项目(20220610)
- DOI：10.14188/j.1671-8852.2024.0081
  中图分类号： R736.1
- 收稿：2024-01-30，
  
  纸质出版：2025-02-25
- 稿件说明：
移动端阅览
李焱,周义.甲状腺癌组织miR‑338‑3p、TCF4表达水平及与临床病理特征和预后的关系[J].武汉大学学报（医学版）,2025,46(02):246-251.

LI Yan,ZHOU Yi.Expression levels of miR‑338‑3p and TCF4 in thyroid cancer tissue and their relationship to the clinical pathological features and prognosis[J].Medical Journal of Wuhan University,2025,46(02):246-251.
李焱,周义.甲状腺癌组织miR‑338‑3p、TCF4表达水平及与临床病理特征和预后的关系[J].武汉大学学报（医学版）,2025,46(02):246-251. DOI： 10.14188/j.1671-8852.2024.0081.

LI Yan,ZHOU Yi.Expression levels of miR‑338‑3p and TCF4 in thyroid cancer tissue and their relationship to the clinical pathological features and prognosis[J].Medical Journal of Wuhan University,2025,46(02):246-251. DOI： 10.14188/j.1671-8852.2024.0081.

摘要

目的

探究甲状腺癌（TC）组织微小RNA‑338‑3p（miR‑338‑3p）、T细胞因子4（TCF4）表达水平及与临床病理特征和预后的相关性。

方法

选择148例河北北方学院附属第一医院2018年9月—2020年9月收治的TC患者为研究对象，术中切除的癌组织作为TC组，癌旁组织作为癌旁组。采用qRT‑PCR法检测组织中miR‑338‑3p、TCF4表达水平；分析TC组织中miR‑338‑3p、TCF4表达水平与临床病理特征及TC患者预后的关系；用多因素Cox回归分析影响TC患者预后的因素。

结果

TC组miR‑338‑3p表达水平均明显低于癌旁组，TCF4表达水平均明显高于癌旁组（

0.05）。Ⅲ~Ⅳ期、低分化和发生淋巴结转移的TC患者miR‑338‑3p低表达、TCF4高表达比例明显高于Ⅰ~Ⅱ期、中高分化和未发生淋巴结转移的TC患者（

0.05）。TC组织miR‑338‑3p低表达患者3年生存率（45.95%）低于miR‑338‑3p高表达患者（74.32%）（

=18.781，

0.001），TC组织TCF4高表达患者3年生存率（41.89%）低于TCF4低表达患者（78.38%）（

=27.978，

0.001）。miR‑338‑3p、TCF4、临床分期、淋巴结转移是影响TC患者预后的相关因素（

0.05）。

结论

TC组织miR‑338‑3p表达水平明显降低，TCF4表达水平明显升高，其与TC患者临床分期、淋巴结转移有着紧密联系，是影响TC患者预后的相关因素。

Abstract

Objective

To investigate the correlation between the expression levels of microRNA‑338‑3p (miR‑338‑3p) and T cell factor 4 (TCF4) in thyroid cancer (TC) tissue with clinical pathological features and prognosis.

Methods

From September 2018 to September 2020

148 TC patients admitted to The First Affiliated Hospital of Hebei North University were involved in this study

their intraoperative resections of TC samples and adjacent tissues were acquired. qRT‑PCR method was applied to detect the expression levels of miR‑338‑3p and TCF4 in tissues. The relationship between the expression levels of miR‑338‑3p and TCF4 in TC tissue and clinical pathological features and prognosis was analyzed. The factors affecting the prognosis of TC patients were analyzed using multivariate Cox regression.

Results

The expression levels of miR‑338‑3p in t

he TC samples were lower than those in the adjacent tissues

and the expression level of TCF4 was higher (both

0.05). The proportions of miR‑338‑3p low expression and TCF4 high expression in TC patients with stage Ⅲ‑Ⅳ

low differentiation

and lymph node metastasis

respectively

were higher than in stage Ⅰ‑Ⅱ

medium to high differentiation

and no lymph node metastasis

respectively (all

0.05). The 3‑year survival rate (45.95%) of patients with low expression of miR‑338‑3p in TC tissue was lower than that of patients with high expression of miR‑338‑3p (74.32%) (

=18.781

0.001)

and the 3‑year survival rate (41.89%) of patients with high expression of TCF4 in TC tissue was lower than that of patients with low expression of TCF4 (78.38%) (

=27.978

0.001). miR‑338‑3p

TCF4

clinical stage

and lymph node metastasis were related factors that affected the prognosis of TC patients (

0.05).

Conclusion

The expression level of miR‑338‑3p in TC tissue is obviously reduced

while the expression level of TCF4 is obviously increased. They are closely related to the clinical stage and lymph node metastasis in TC patients

and are related factors affecting the prognosis of TC patients.

关键词

Keywords

references

Grimm D . Recent advances in thyroid cancer research [J ] . Int J Mol Sci , 2022 , 23 ( 9 ): 4631 .

Suzuki K , Iwai H , Utsunomiya K , et al . Combination therapy with lenvatinib and radiation significantly inhibits thyroid cancer growth by uptake of tyrosine kinase inhibitor [J ] . Exp Cell Res , 2021 , 398 ( 1 ): 112390 .

李宗禹 , 徐金锴 , 赖婧玥 , 等 . MiR‑93‑5p靶向CCNG2基因对甲状腺癌细胞增殖和凋亡的影响及其机制 [J ] . 现代肿瘤医学 , 2020 , 28 ( 19 ): 3325 ‑ 3330 .

Li Z Y , Xu J K , Lai J Y , et al . The effect and mechanism of miR‑93‑5p targeting CCNG2 gene on proliferation and apoptosis of thyroid caner cells [J ] . J Mod Oncol , 2020 , 28 ( 19 ): 3325 ‑ 3330 .

Ricarte‑Filho J C , Casado‑Medrano V , Reichenberger E , et al . DICER1 RNase Ⅲb domain mutations trigger widespread miRNA dysregulation and MAPK activation in pediatric thyroid cancer [J ] . Front Endocrinol , 2023 , 14 : 1083382 .

Chen J Y , Liu Z , Zhong Y , et al . Circ_0124208 promotes the progression of hepatocellular carcinoma by regulating the miR‑338‑3p/LAMC1 axis [J ] . Mol Biotechnol , 2023 , 65 ( 11 ): 1750 ‑ 1763 .

Lu H , Zhang Q , Sun Y Q , et al . LINC00689 induces gastric cancer progression via modulating the miR‑338‑3p/HOXA3 axis [J ] . J Gene Med , 2020 , 22 ( 12 ): e3275 .

樊芳 , 关慧娟 . Circ_0000003通过调控miR‑338‑3p/IRS2轴调控甲状腺癌细胞增殖、转移和凋亡 [J ] . 中国临床药理学杂志 , 2021 , 37 ( 4 ): 421 ‑ 424 .

Fan F , Guan H J . Circ_0000003 regulates the proliferation, metastasis and apoptosis of thyroid carcinoma cells by regulating the miR‑338‑3p/IRS2 axis [J ] . Chin J Clin Pharmacol , 2021 , 37 ( 4 ): 421 ‑ 424 .

Wang Y , Zheng L , Shang W , et al . Wnt/beta‑catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer [J ] . Cell Death Differ , 2022 , 29 ( 11 ): 2190 ‑ 2202 .

Wang R , Cai J D , Xie S N , et al . T cell factor 4 is involved in papillary thyroid carcinoma via regulating long non‑coding RNA HCP5 [J ] . Technol Cancer Res Treat , 2020 , 19 : 1533033820983290 .

中国抗癌协会妇科肿瘤专业委员会 . 甲状腺癌诊断与治疗指南(第四版) [J ] . 中国实用妇科与产科杂志 , 2018 , 34 ( 6 ): 613 ‑ 622 .

Professional Committee of Gynecological Oncology, Chinese Anti‑Cancer Association . Guidelines for diagnosis and treatment of thyroid cancer (4th edition) [J ] . Chinese Journal of Applied Gynecology & Obstetrics , 2018 , 34 ( 6 ): 613 ‑ 622 .

Qu N , Hui Z G , Shen Z X , et al . Thyroid cancer and COVID‑19: Prospects for therapeutic approaches and drug development [J ] . Front Endocrinol , 2022 , 13 : 873027 .

Zhang H P , Zhao Y C , Wu Q , et al . The prognostic value of lymph node metastasis and the eighth edition of AJCC for patients with anaplastic thyroid cancer [J ] . Clin Endocrinol , 2021 , 95 ( 3 ): 498 ‑ 507 .

Prete A , Borges de Souza P , Censi S , et al . Update on fundamental mechanisms of thyroid cancer [J ] . Front Endocrinol , 2020 , 11 : 102 .

蔡涛 , 宋小兵 . MiR‑19a通过调节PTEN对肝癌的抑制作用 [J ] . 武汉大学学报(医学版) , 2022 , 43 ( 4 ): 604 ‑ 607 .

Cai T , Song X B . Inhibition of miR‑19a on hepatocellular carcinoma by regulating PTEN [J ] . Med J Wuhan Univ , 2022 , 43 ( 4 ): 604 ‑ 607 .

He J , Wang J , Li S , et al . Hypoxia‑inhibited miR‑338‑3p suppresses breast cancer progression by directly targeting ZEB2 [J ] . Cancer Sci , 2020 , 111 ( 10 ): 3550 ‑ 3563 .

Xu P , Cheng S Y , Wang X W , et al . The hsa_circ_0039857/miR‑338‑3p/RAB32 axis promotes the malignant progression of colorectal cancer [J ] . BMC Gastroenterol , 2022 , 22 ( 1 ): 530 .

Dou X L , Xia F D , Li X Y . Circ_0003747 promotes thyroid cancer progression by sponging miR‑338‑3p to upregulate PLCD3 expression [J ] . Epigenetics , 2023 , 18 ( 1 ): 2210339 .

He M Q , Wan J F , Zeng H F , et al . miR‑133a‑5p suppresses gastric cancer through TCF4 down‑regulation [J ] . J Gastrointest Oncol , 2021 , 12 ( 3 ): 1007 ‑ 1019 .

Tu W , Gong J , Zhou Z Z , et al . TCF4 enhances hepatic metastasis of colorectal cancer by regulating tumor‑associated macrophage via CCL2/CCR2 signaling [J ] . Cell Death Dis , 2021 , 12 : 882 .

Yi S J , Liu L Q , Chen Z W . lncRNA EGFEM1P promotes thyroid cancer progression by acting as an miR‑369‑3p sponge and upregulating TCF4 [J ] . Oncol Lett , 2022 , 24 ( 6 ): 456 .

王思寅 , 董颖 , 滕立勤 . 甲状腺癌组织中miR‑93‑5p、BRMS1L的表达水平及其临床意义 [J ] . 实用癌症杂志 , 2023 , 38 ( 4 ): 538 ‑ 541 .

Wang S Y , Dong Y , Teng L Q . Expression of mirR‑93‑5p and BRMS1L in thyroid carcinoma and its clinical significance [J ] . Pract J Cancer , 2023 , 38 ( 4 ): 538 ‑ 541 .

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

特发性肺纤维化生存预后预测模型的建立及验证

急性脑梗死患者血清circ_0003204和miR‑532‑3p水平变化及其与炎性因子水平的相关性

ASPM基因在肝细胞癌中的表达分析及其预后价值

胃癌化疗期营养管理的临床研究进展

生物力学损伤通过下调TGF⁃β/Smad3信号通路诱导L929细胞线粒体自噬